DelveInsight’s “Becker Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Becker Muscular Dystrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Becker Muscular Dystrophy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Becker Muscular Dystrophy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Becker Muscular Dystrophy: An Overview
Becker Muscular Dystrophy (BMD) is an inherited muscle structure disorder that results in progressive deterioration of limbs, and cardiac and skeletal muscles. However, the involuntary muscles are not affected. BMD is a milder version of Duchenne Muscular Dystrophy (DMD). BMD usually begins in the teens or early adulthood, and the course is slower and far less predictable than that of DMD.
Early symptoms of BMD are cramps after exercising, and later in life, the person begins to experience problems while walking quickly or running. Other noticeable symptoms besides weakness are falling, feeling “worn out,” and changes in the skeletal system. Muscle weakness often affects the legs and pelvis, and slowly gets worse. Few affected individuals even have learning problems, but these cases are typically minor.
BMD is caused due to a deformity of the DMD gene, which is an X-linked disorder (therefore, females are the carriers of this defect). This abnormality in the gene produces defective dystrophin protein. This protein helps stabilize and protect muscle fibers and may play a role in chemical signaling within cells. Muscle cells without fully functional dystrophin become damaged as muscles contract and relax with use. They then weaken and die over time, leading to muscle weakness and heart problems in people with BMD.
BMD primarily affects males. However, the age of onset and rate of progression can vary. Muscle weakness usually becomes apparent between the ages of 5–15. In some cases, heart involvement (cardiomyopathy) can also be the first sign of BMD. This form of heart disease weakens the cardiac muscle, preventing the heart from pumping blood efficiently. Cardiomyopathy typically begins in adolescence and later, the heart muscle becomes enlarged, and the heart problems develop into a condition known as dilated cardiomyopathy.
Becker Muscular Dystrophy Market Key Facts
-
According to the Genetic and Rare Diseases Information Center, the prevalence of Becker Muscular Dystrophy is estimated to be between 17–27 cases per million people. This means that at a given time, about one in 37,000 to one in 59,000 people are living with Becker Muscular Dystrophy.
-
According to the Centers for Disease Control and Prevention (CDC), the estimated prevalence of Duchenne and Becker muscular dystrophy (Becker Muscular Dystrophy) was one in every 7,250 males aged 5–24 years. However, the prevalence of DMD was found to be three times higher than the prevalence of Becker Muscular Dystrophy.
-
According to a study conducted by Walter et al. (2017), titled “Recent developments in Duchenne muscular dystrophy: facts and numbers”, the worldwide prevalence of Becker Muscular Dystrophy is estimated to be 1.53 per 100,000 males and according to recent calculations of the German population, about 600 Becker Muscular Dystrophy patients are supposed to live in Germany.
Becker Muscular Dystrophy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Becker Muscular Dystrophy pipeline therapies. It also thoroughly assesses the Becker Muscular Dystrophy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Becker Muscular Dystrophy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Becker Muscular Dystrophy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Becker Muscular Dystrophy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Becker Muscular Dystrophy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Becker Muscular Dystrophy Epidemiology, Segmented as –
-
Prevalent Cases of Becker Muscular Dystrophy
-
Age-specific Prevalent Cases of Becker Muscular Dystrophy
-
Diagnosed and Treatable Cases of Becker Muscular Dystrophy
Becker Muscular Dystrophy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Becker Muscular Dystrophy market or expected to be launched during the study period. The analysis covers the Becker Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Becker Muscular Dystrophy drugs based on their sale and market share.
The report also covers the Becker Muscular Dystrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Becker Muscular Dystrophy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Becker Muscular Dystrophy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/becker-muscular-dystrophy-market
Becker Muscular Dystrophy Therapeutics Analysis
The treatment of BMD focuses on lessening the symptoms associated with it. There is no cure, but treatments are available to help with symptoms and maximize muscle function. It is vital that a person with BMD stay in shape and continue to use their muscles. Though there are no FDA-approved drugs for the treatment of BMD, but many different therapies are currently under investigation for its treatment.
Medications that lessen the overall workload of the heart are sometimes prescribed for BMD. Evidence suggests that treatment with angiotensin-converting enzyme (ACE) inhibitors and beta blockers can slow the course of cardiac muscle deterioration in BMD if the medications are started as soon as abnormalities appear on an echocardiogram (imaging of the heart), but before symptoms occur.
Several major pharma and biotech companies are developing therapies for Becker Muscular Dystrophy. Currently, Italfarmaco is leading the therapeutics market with its Becker Muscular Dystrophy drug candidates in the most advanced stage of clinical development.
Becker Muscular Dystrophy Companies Actively Working in the Therapeutics Market Include
-
Italfarmaco
-
Immunoforge Co., Ltd.
-
Edgewise Therapeutics
-
Epirium Bio
-
Ultragenyx
-
Strykagen
And Many Others
Emerging and Marketed Becker Muscular Dystrophy Therapies Covered in the Report Include:
-
Givinostat: Italfarmaco – Givinostat (INN) or gavinostat (originally ITF2357) is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. It is a hydroxamate used in the form of its hydrochloride. Since Givinostat acts on the pathogenetic events downstream of the genetic defects, it is potentially a treatment for the whole DMD and BMD population and to counter the disease pathogenetic events in all muscular districts. The drug is currently being evaluated in Phase II clinical to treat Becker muscular dystrophy.
-
EDG-5506: Edgewise Therapeutics – Edgewise Therapeutics Continued to advance a Phase I MAD study of EDG-5506, a small molecule drug candidate designed to arrest muscle fiber breakdown in Duchenne and Becker muscular dystrophy (DMD and BMD).
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/becker-muscular-dystrophy-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Becker Muscular Dystrophy Competitive Intelligence Analysis
4. Becker Muscular Dystrophy Market Overview at a Glance
5. Becker Muscular Dystrophy Disease Background and Overview
6. Becker Muscular Dystrophy Patient Journey
7. Becker Muscular Dystrophy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Becker Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Becker Muscular Dystrophy Unmet Needs
10. Key Endpoints of Becker Muscular Dystrophy Treatment
11. Becker Muscular Dystrophy Marketed Therapies
12. Becker Muscular Dystrophy Emerging Drugs and Latest Therapeutic Advances
13. Becker Muscular Dystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Becker Muscular Dystrophy Market Outlook (In US, EU5, and Japan)
16. Becker Muscular Dystrophy Companies Active in the Market
17. Becker Muscular Dystrophy Access and Reimbursement Overview
18. KOL Views on the Becker Muscular Dystrophy Market
19. Becker Muscular Dystrophy Market Drivers
20. Becker Muscular Dystrophy Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/becker-muscular-dystrophy-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market
“Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the CDKL5 market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research